|Bid||51.45 x 2200|
|Ask||51.53 x 3100|
|Day's Range||50.30 - 51.64|
|52 Week Range||38.82 - 61.71|
|Beta (5Y Monthly)||0.71|
|PE Ratio (TTM)||11.62|
|Earnings Date||Jul 28, 2022|
|Forward Dividend & Yield||1.60 (3.19%)|
|Ex-Dividend Date||Jul 28, 2022|
|1y Target Est||58.62|
The U.S. Centers for Disease Control and Prevention said on Friday it had recommended Moderna's COVID-19 vaccine for children and adolescents aged 6 to 17, allowing a rollout of the shots to begin for that age group. A rival vaccine from Pfizer and BioNTech, based on similar messenger RNA technology, has been available for teens for more than a year and since October for children aged 5 to 11. On Saturday, the CDC recommended Moderna's shot for children aged six months to five years, and Pfizer-BioNTech's vaccine for children aged six months to four years.
NEW YORK, June 24, 2022--Pfizer Inc. (NYSE: PFE) invites investors and the general public to view and listen to a webcast of a conference call with investment analysts at 10 a.m. EDT on Thursday, July 28, 2022. The purpose of the call is to provide an update on Pfizer’s results, as reflected in the company’s Second Quarter 2022 Performance Report, to be issued that morning.
EMA's Committee for Medicinal Products for Human Use recommends granting marketing approval to Novavax's (NVAX) COVID-19 vaccine for use in adolescents. The stock rises 13.9%.